Literature DB >> 11382923

Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate.

K Lundmark1, P K Tran, M G Kinsella, A W Clowes, T N Wight, U Hedin.   

Abstract

Smooth muscle cell migration, proliferation, and deposition of extracellular matrix are key events in atherogenesis and restenosis development. To explore the mechanisms that regulate smooth muscle cell function, we have investigated whether perlecan, a basement membrane heparan sulfate proteoglycan, modulates interaction between smooth muscle cells and other matrix components. A combined substrate of fibronectin and perlecan showed a reduced adhesion of rat aortic smooth muscle cells by 70-90% in comparison to fibronectin alone. In contrast, perlecan did not interfere with cell adhesion to laminin. Heparinase treated perlecan lost 60% of its anti-adhesive effect. Furthermore, heparan sulfate as well as heparin reduced smooth muscle cell adhesion when combined with fibronectin whereas neither hyaluronan nor chondroitin sulfate had any anti-adhesive effects. Addition of heparin as a second coating to a preformed fibronectin matrix did not affect cell adhesion. Cell adhesion to the 105- and 120 kDa cell-binding fragments of fibronectin, lacking the main heparin-binding domains, was also inhibited by heparin. In addition, co-coating of fibronectin and (3)H-heparin showed that heparin was not even incorporated in the substrate. Morphologically, smooth muscle cells adhering to a substrate prepared by co-coating of fibronectin and perlecan or heparin were small, rounded, lacked focal contacts, and showed poorly developed stress fibers of actin. The results show that the heparan sulfate chains of perlecan lead to altered interactions between smooth muscle cells and fibronectin, possibly due to conformational changes in the fibronectin molecule. Such interactions may influence smooth muscle cell function in atherogenesis and vascular repair processes. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11382923     DOI: 10.1002/jcp.1094

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

2.  The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling.

Authors:  Megan S Lord; Christine Y Chuang; James Melrose; Michael J Davies; Renato V Iozzo; John M Whitelock
Journal:  Matrix Biol       Date:  2014-02-06       Impact factor: 11.583

3.  Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma.

Authors:  Galina M Kazanskaya; Alexandra Y Tsidulko; Alexander M Volkov; Roman S Kiselev; Anastasia V Suhovskih; Vyacheslav V Kobozev; Alexei S Gaytan; Svetlana V Aidagulova; Alexei L Krivoshapkin; Elvira V Grigorieva
Journal:  Histochem Cell Biol       Date:  2018-01-10       Impact factor: 4.304

Review 4.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

5.  Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney.

Authors:  Maarit Rossi; Hiroyuki Morita; Raija Sormunen; Sari Airenne; Marjut Kreivi; Ling Wang; Naomi Fukai; Bjorn R Olsen; Karl Tryggvason; Raija Soininen
Journal:  EMBO J       Date:  2003-01-15       Impact factor: 11.598

6.  Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling.

Authors:  Heather A Walker; John M Whitelock; Pamela J Garl; Raphael A Nemenoff; Kurt R Stenmark; Mary C M Weiser-Evans
Journal:  Mol Biol Cell       Date:  2003-01-26       Impact factor: 4.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.